US Daily Brief: Today‘s Research – July 23, 2026

Research evidence excerpt

US Daily Brief: Today‘s Research – July 23, 2026

Global Research

23 July 2026ab

US Daily Brief Equities

AmericasToday's Research – July 23, 2026

Joseph Parkhill

Product Manager

Alphabet Inc. - Class A (GOOGL, Neutral, $379 from $400) - Revenue Growth Was joseph.parkhill@ubs.com

+1-212-713 3716

Already Dialed In (Stephen Ju)

Greater upward bias on costs versus revenue Peter Lennox-King

peter.lennox-king@ubs.com

Knight-Swift Transp (KNX, Buy, $94) - TL Rate Upcycle on Track: 2Q Beat + 3Q +1-212-713 3215

Upside Guide (Thomas Wadewitz)

Ryan BellKNX 2Q EPS beat consensus, with truckload margins improving and pricing visibility

supporting favorable 2026–27 conditions ryan-b.bell@ubs.com

+1-212-713 1233

CSX Corporation (CSX, Buy, $54) - Upside 2Q + Solid Guide ==> Margin Story On

Track (Thomas Wadewitz)

We maintain our EPS estimates for 2H26 and 2027 which are above consensus

O'Reilly Automotive, Inc. (ORLY, Buy, $120) - Cleared for Takeoff (Michael Lasser)

Take a look at our preview ahead of ORLY's 2Q earnings.

US Beverages - UBS Evidence Lab Inside: Sugar Crash or Second Wind Ahead? A Deep

Dive On The Energy Drink Category (Peter Grom)

Results from the 8th Energy Drink Survey from UBS Evidence Lab reinforces our bullish

view on the category but competitive pressures likely to remain

Ideaya Biosciences Inc (IDYA, Buy, $50) - NDR Takeaways: Rolling Filing with FDA on

Uveal Melanoma; New PRMT5/RAS Combo Could Be Significant Upside Catalyst

Pending Data (Michael Yee)

We hosted IDYA mgmt for a packed NDR and remain upbeat about the stock

MBX Biosciences (MBX, Buy, $90 from $60) - *SLIDES* Q4 Obesity Readout Should

Be Strong; Raise PT to $90 + Reiterate Top Pick (Michael Yee)

We remain bullish on the stock into the upcoming 12-week Phase I obesity readout in